Drug Development
Peptide p160 with affinity for neuroblastoma cells was developed
Published in Cancer Weekly, August 8th, 2006
According to a study from Germany, "Drug-targeting strategies can increase the efficacy and reduce the side effects and toxicity of conventional chemotherapy or may lead to new radiolabeled molecules useful for diagnosis and therapy. To identify and characterize new carrier molecules, we evaluated a peptide that had been identified by phage display technology. The peptide p160 was prepared by solid-phase peptide synthesis and radiolabeled with I-125 or I-131."
"The radiolabeled peptide and derivatives of it were used to study binding and internalization in vitro and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-08)
More Articles from Cancer Weekly
- Cancer Registries
Period estimates of cancer patient survival deemed more up-to-date than complete estimates - Diagnostics
Modified nucleosides and creatinine in urine samples used in early cancer detection - Diet & Nutrition
Consumption advisories of farmed salmon based on cancer risk reported - Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumor apoptosis induced by flavopiridol - Prostate Cancer
Prostate cancer risk in African American men linked to common nonsense mutation in EphB2 - Adrenocortical Cancer
Adrenocortical carcinoma management depends on better understanding of molecular pathogenesis - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
